Craig Hallum Initiates Coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX)

Posted by Linda Flegge on Feb 21st, 2025

Research analysts at Craig Hallum initiated coverage on shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) in a report released on Friday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $12.00 price target on the stock. Craig Hallum’s target price suggests a potential upside of 238.03% from the company’s current price.

EPRX has been the topic of a number of other reports. Rodman & Renshaw started coverage on shares of Eupraxia Pharmaceuticals in a report on Thursday, November 14th. They issued a “buy” rating and a $9.00 target price on the stock. RODMAN&RENSHAW raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Thursday, November 14th.

Get Our Latest Analysis on Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Stock Performance

Shares of EPRX stock opened at $3.55 on Friday. The firm’s 50-day moving average is $3.13 and its 200-day moving average is $2.90. The stock has a market cap of $126.56 million and a price-to-earnings ratio of -4.93. Eupraxia Pharmaceuticals has a 52-week low of $2.20 and a 52-week high of $5.22.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Millennium Management LLC bought a new position in Eupraxia Pharmaceuticals in the 4th quarter valued at about $31,000. Raymond James Financial Inc. bought a new position in Eupraxia Pharmaceuticals in the 4th quarter valued at about $37,000. Finally, Bank of Montreal Can raised its holdings in Eupraxia Pharmaceuticals by 15.2% in the 4th quarter. Bank of Montreal Can now owns 56,750 shares of the company’s stock valued at $178,000 after acquiring an additional 7,500 shares during the period.

About Eupraxia Pharmaceuticals

(Get Free Report)

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.